AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17172427
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg twice daily for 5 to 15 days before surgery
Trial: 14517580
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate concentrations (1-100 microg/mL)
Trial: 11081318
Drug: Transdermal dihydrotestosterone
RxNorm normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal dihydrotestosterone (DHT) treatment for 12 weeks
Trial: 29672831
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg riluzole
Trial: 8721257
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg riluzole
Trial: 1416129
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia by epidural infusion of buprenorphine (3 micrograms/mL) with 0.03% bupivacaine
Trial: 1416129
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia by epidural infusion of fentanyl (2 micrograms/mL) with 0.03% bupivacaine
Trial: 3986085
Drug: Oral secoverine
RxNorm normalized name: fenoverine
DrugBank: Fenoverine (DB13042)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral secoverine hydrochloride
Trial: 29374733
Drug: Rectus sheath
RxNorm normalized name: Sus scrofa rectum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectus sheath block (RSB) analgesia - single-dose
Trial: 29374733
Drug: Rectus sheath
RxNorm normalized name: Sus scrofa rectum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectus sheath block (RSB) analgesia - repeated-dose
Trial: 29374733
Drug: Rectus sheath
RxNorm normalized name: Sus scrofa rectum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectus sheath block (RSB) analgesia - continuous infusion
Trial: 25223547
Drug: One-day bowel
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-day bowel preparation with Miralax®
Trial: 25223547
Drug: Three-day bowel
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-day bowel preparation with Miralax®
Trial: 11007446
Drug: diphenhydramine 50
RxNorm normalized name: diphenhydrAMINE 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diphenhydramine 50 mg-8 hr TIB
Trial: 8436497
Drug: Trazodone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (1 mg/kg a day divided into 3 doses) for 12 weeks
Trial: 29278443
Drug: Solution-focused approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution-focused approach interview technique (8 interviews at 2-week intervals, 30-45 min each)
Trial: 29278443
Drug: Solution-focused approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution-focused approach interview technique
Trial: 16579997
Drug: CC+MET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC+MET
Trial: 9391292
Drug: Ibopamine 100
RxNorm normalized name: ibopamine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine 100 mg three times daily
Trial: 7505523
Drug: Continuous diluted
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous diluted intravesical instillation of bleomycin (120 mg/2,000 ml saline solution/day for 3 days), instillation BCG (40 mg/40 ml saline solution/weekly 6 times), and UFT (400 mg orally/day for 2 years maximum)
Trial: 3569448
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg ambroxol daily
Trial: 20232195
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (adequate analgesia, osteoporosis medication, individualized physiotherapy or braces)
Trial: 12211220
Drug: Estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy in postmenopausal women
Trial: 12211220
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E therapy to reduce cardiovascular risk
Trial: 23878167
Drug: IFX dose
RxNorm normalized name: IFx-Hu2.0
DrugBank: IFx-Hu2.0 (DB18396)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFX dose intensification (5 mg/kg every 4 weeks)
Trial: 23878167
Drug: Interventions based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventions based on serum IFX and IFX antibody levels using the proposed algorithm
Trial: 16285179
Drug: Autologous tumour
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous tumour cell vaccine (n = 9)
Trial: 9084515
Drug: 0.5% interpleural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% interpleural bupivacaine (10 ml)
Trial: 1912105
Drug: m-CPP (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-CPP (up to 80 mg/day for 16 days)
Trial: 29432379
Drug: Dexmedetomidine 1 μg kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg kg over 10 min before induction, then 0.4 μg kg h
Trial: 29432379
Drug: Dexmedetomidine 1 μg kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg kg over 10 min before induction, then 0.6 μg kg h
Trial: 29432379
Drug: Dexmedetomidine 0.6 μg kg h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.6 μg kg h
Trial: 29432379
Drug: Dexmedetomidine 0.4 μg kg h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.4 μg kg h
Trial: 26766541
Drug: Warfarin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (target international normalized ratio, 2‐3)
Trial: 25516016
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg ibuprofen three times a day for three days
Trial: 25516016
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg mecillinam three times a day for three days
Trial: 23649063
Drug: Gel containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel containing 6% potassium nitrate and 0.11% fluoride ions
Trial: 23782487
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) administration
Trial: 20970637
Drug: Placebo (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5% dextrose solution)
Trial: 18489783
Drug: Zafirlukast 20
RxNorm normalized name: zafirlukast 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast 20 mg twice daily for 12 weeks (Group I)
Trial: 18489783
Drug: Zafirlukast 20
RxNorm normalized name: zafirlukast 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast 20 mg twice daily for 12 weeks (Group II)
Trial: 15634273
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 50 mg twice daily
Trial: 21438804
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 150 mg twice daily
Trial: 15634273
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 300 mg once daily
Trial: 15634273
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 225 mg twice daily
Trial: 16036023
Drug: Ventricular assist
RxNorm normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventricular assist devices as destination therapy
Trial: 10996579
Drug: Bacterial load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacterial load of 10(6) to 10(7) CFU/mL
Trial: 10996579
Drug: Bacterial load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacterial load of 10(7) to 10(8) CFU/mL
Trial: 10996579
Drug: Bacterial load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacterial load of 10(8) or greater CFU/mL
Trial: 9115022
Drug: Bronchodilator drugs
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator drugs
Trial: 3546151
Drug: Ofloxacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (100 mg, b.i.d. for 7 days)
Trial: 3546151
Drug: Ciprofloxacin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (250 mg, b.i.d. for 7 days)
Trial: 24880581
Drug: Eye Movement
RxNorm normalized name: JOINT MOVEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye Movement Desensitization and Reprocessing therapy (n=10)
Trial: 24880581
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (n=10)
Trial: 20424140
Drug: Lipid heparin
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid heparin infusion (LHI) inducing physiological elevations of FFAs
Trial: 20424140
Drug: Discontinued insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discontinued insulin infusion
Trial: 20424140
Drug: Continuous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous insulin supply
Trial: 18793446
Drug: Physiotherapist-delivered OA
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapist-delivered OA education control treatment (8 individual sessions over 12 weeks)
Trial: 16182685
Drug: Oral dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dietary supplements
Trial: 21336185
Drug: Shenmai injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenmai injection (SMI)
Trial: 6510453
Drug: Penbutolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol (40 mg)
Trial: 159057
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (30 mg)
Trial: 29771596
Drug: ExPEC4V vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ExPEC4V vaccine (4, 8, and 16 µg PS/serotype)
Trial: 21998259
Drug: AHR strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AHR strategy (titrating inhaled corticosteroid against mannitol PD(10))
Trial: 20480225
Drug: Celecoxib 800
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 800 mg/day during cycles 5-8
Trial: 20480225
Drug: Trastuzumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (8 mg/kg then 6 mg/kg IV every 3 weeks)
Trial: 20480225
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment (control for HER2-negative)
Trial: 20480225
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional preoperative treatment (control for HER2-positive)
Trial: 18705755
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Nigella sativa seed extract twice a day
Trial: 18705755
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Nigella sativa seed extract twice a day
Trial: 15744449
Drug: 25-hydroxy vitamin
RxNorm normalized name: 1α-hydroxy-vitamin D3
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-hydroxy vitamin D levels below 20 ng/ml
Trial: 15744449
Drug: 25-hydroxy vitamin
RxNorm normalized name: 1α-hydroxy-vitamin D3
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-hydroxy vitamin D levels below 30 ng/ml
Trial: 14710908
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of isotonic saline (placebo)
Trial: 10070048
Drug: Mild hyperglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild hyperglycemia (approximately 10 mmol/l)
Trial: 10070048
Drug: Euglycemia (approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycemia (approximately 4 mmol/l)
Trial: 7668024
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg erythromycin q.i.d.
Trial: 7668024
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg erythromycin i.v. (single dose)
Trial: 2107773
Drug: EMLA and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA and glyceryl trinitrate ointment
Trial: 7468946
Drug: Nebulized racemic
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized racemic epinephrine (Micronephrine) at a dose of 0.9 mg/kg body-weight
Trial: 7468946
Drug: Nebulized salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized salbutamol at a dose of 0.15 mg/kg body-weight
Trial: 3771813
Drug: Propranolol 640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 640 mg/day
Trial: 31083192
Drug: Fu's subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fu's subcutaneous needling (FSN) combined with usual care (UC) for 4 weeks
Trial: 23094314
Drug: Calcipotriene ointment
RxNorm normalized name: Calcipotriene Ointment
DrugBank: Calcipotriol (DB02300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcipotriene ointment 0.005% applied twice daily
Trial: 15153904
Drug: Tacrolimus ointment
RxNorm normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus ointment 0.1% applied twice daily
Trial: 23094314
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of calcipotriene and tacrolimus (morning calcipotriene and evening tacrolimus)
Trial: 18007570
Drug: Guideline concordant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline concordant treatments for mixed episodes
Trial: 18007570
Drug: Guideline concordant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline concordant treatments for hypomanic/manic episodes
Trial: 18007570
Drug: Guideline concordant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline concordant treatments for depressive episodes
Trial: 12010266
Drug: Ketorolac 20
RxNorm normalized name: ketorolac 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 20 mg intravenously in the non-operative arm before surgery (systemic presurgery group)
Trial: 12010266
Drug: Ketorolac 20
RxNorm normalized name: ketorolac 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 20 mg intravenously to the operative arm after tourniquet inflation (regional presurgery group)
Trial: 12010266
Drug: Ketorolac 20
RxNorm normalized name: ketorolac 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 20 mg intravenously in the non-operative arm after surgery (systemic postsurgery group)
Trial: 31099864
Drug: Payments from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Payments from pharmaceutical companies
Trial: 25856243
Drug: Standard biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard biofeedback protocol plus daily home use of a Peritron perineometer (intervention)
Trial: 23419231
Drug: Quetiapine 400
RxNorm normalized name: quetiapine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 400 mg/d
Trial: 22379909
Drug: Isobaric bypivacain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric bypivacain (5 mg/ml)
Trial: 22379909
Drug: Ropivacain (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacain (5 mg/ml)
Trial: 15210591
Drug: Anemia (Hb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anemia (Hb < or =12.0 g/dL)
Trial: 15210591
Drug: Higher baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher baseline hemoglobin (1 g/dL increase)
Trial: 8615506
Drug: Lansoprazole-lansoprazole (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole-lansoprazole (Group L-L)
Trial: 8615506
Drug: Lansoprazole-placebo (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole-placebo (Group L-P)
Trial: 8615506
Drug: Placebo-lansoprazole (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-lansoprazole (Group P-L)
Trial: 4009215
Drug: Involved field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved field radiation treatment (RTIF)
Trial: 4009215
Drug: Extended field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended field radiation treatment (RTEF)
Trial: 30286238
Drug: Guided internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet-based cognitive behavioral therapy for 8 weeks
Trial: 30286238
Drug: Guided internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet-based cognitive behavioral therapy
Trial: 28003203
Drug: Cocoa flavanols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa flavanols (0-820 mg) with methylxanthines (0-220 mg)
Trial: 28003203
Drug: Cocoa flavanols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa flavanols (0-820 mg)
Trial: 26408732
Drug: Directly stopped
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly stopped VEGFR TKI treatment
Trial: 26408732
Drug: Continued VEGFR
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued VEGFR TKI treatment for another two weeks
Trial: 24047919
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg Ca/d
Trial: 18205185
Drug: Immediate-start zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Immediate-start zoledronic acid (4 mg intravenously biannually for 5 years)
Trial: 18205185
Drug: Delayed-start zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Delayed-start zoledronic acid (4 mg intravenously biannually for 5 years)
Trial: 18192897
Drug: Simvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (80 mg/day)
Trial: 14519799
Drug: Rectal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal infusion of acetate (60 mmol/L), propionate (20 mmol/L), and butyrate (20 mmol/L)
Trial: 14519799
Drug: Butyrate-containing infusions
RxNorm normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butyrate-containing infusions
Trial: 14519799
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of three SCFA
Trial: 11097191
Drug: Treatment readiness
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment readiness training
Trial: 1417159
Drug: two annual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two annual doses of ivermectin 100 mcg/kg
Trial: 1417159
Drug: three semi‐annual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three semi‐annual doses of ivermectin 100 mcg/kg
Trial: 1417159
Drug: two annual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two annual doses of diethylcarbamazine (DEC) 3 mg/kg
Trial: 1417159
Drug: three semi‐annual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three semi‐annual doses of diethylcarbamazine (DEC) 3 mg/kg
Trial: 1417159
Drug: two annual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two annual doses of diethylcarbamazine (DEC) 6 mg/kg
Trial: 4074419
Drug: 35 mg
RxNorm normalized name: papain 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg bencyclane intravenously
Trial: 4074419
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg bencyclane intravenously
Trial: 4074419
Drug: 71 mg
RxNorm normalized name: nilotinib 71 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 71 mg bencyclane orally as a solution in water
Trial: 4074419
Drug: 143 mg
RxNorm normalized name: ferrous sulfate 143 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 143 mg bencyclane orally as a solution in water
Trial: 4074419
Drug: Intravenous bencyclane
RxNorm normalized name: bencyclane
DrugBank: Bencyclane (DB13488)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bencyclane
Trial: 19281922
Drug: Rosuvastatin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin therapy
Trial: 18408611
Drug: CAF-5 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF-5 (5 mg.kg(‐1))
Trial: 18408611
Drug: CAF-3 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF-3 (3 mg.kg(‐1))
Trial: 18408611
Drug: CAF-1 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF-1 (1 mg.kg(‐1))
Trial: 8433469
Drug: Air suspension
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air suspension bed